{"id":"camrelizumab-plus-tp","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Chemotherapy-related myelosuppression"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:28:59.990796","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Camrelizumab binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with PD-L1/PD-L2 ligands on tumor cells and restoring anti-tumor immune responses. The combination with TP chemotherapy (taxane and platinum-based regimen) provides dual mechanisms: direct cytotoxic tumor killing plus enhanced immunological attack through checkpoint inhibition and chemotherapy-induced immunogenic cell death.","oneSentence":"Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor immunity, combined with TP (paclitaxel and cisplatin) chemotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:54.500Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Esophageal squamous cell carcinoma (Phase 3 trial)"},{"name":"Advanced or metastatic solid tumors (investigational)"}]},"_fixedFields":["pubmed(4)"],"trialDetails":[{"nctId":"NCT07471815","phase":"PHASE2","title":"Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harbin Medical University","startDate":"2026-03-04","conditions":"Breast Cancer Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT06086457","phase":"PHASE3","title":"PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-02-04","conditions":"Esophageal Neoplasms","enrollment":436},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT05798793","phase":"PHASE3","title":"Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Hospital of Stomatology, Wuhan University","startDate":"2023-11-21","conditions":"Oral Squamous Cell Carcinoma","enrollment":309},{"nctId":"NCT06092957","phase":"PHASE3","title":"Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-09","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":504},{"nctId":"NCT05183958","phase":"PHASE2","title":"A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-12-31","conditions":"Esophageal Cancer","enrollment":118}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"recentPublications":[{"date":"2026","pmid":"41836437","title":"Efficacy and safety of neoadjuvant immunotherapy in locally advanced resectable esophageal squamous cell carcinoma: a network meta-analysis and real-world study.","journal":"Frontiers in immunology"},{"date":"2026 Jan 27","pmid":"41588455","title":"Analysis of the efficacy of camrelizumab/cetuximab neoadjuvant therapy in patients with loco-regionally advanced laryngeal and hypopharyngeal cancer and the prognostic value of NLR/SII.","journal":"World journal of surgical oncology"},{"date":"2025","pmid":"40079001","title":"Immune repertoire sequencing reveals differences in treatment response to camrelizumab plus platinum-based chemotherapy in advanced ESCC.","journal":"Frontiers in immunology"},{"date":"2024 Sep","pmid":"38956195","title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.","journal":"Nature medicine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SHR-1210 plus Docetaxel, Cisplatin"],"phase":"phase_3","status":"active","brandName":"Camrelizumab plus TP","genericName":"Camrelizumab plus TP","companyName":"Hospital of Stomatology, Wuhan University","companyId":"hospital-of-stomatology-wuhan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to enhance anti-tumor immunity, combined with TP (paclitaxel and cisplatin) chemotherapy. Used for Esophageal squamous cell carcinoma (Phase 3 trial), Advanced or metastatic solid tumors (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}